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A B S T R A C T
Background
US Centers for Disease Control guidelines recommend replacement of peripheral intravenous catheters (PIVC) no more frequently
than every 72 to 96 hours. Routine replacement is thought to reduce the risk of phlebitis and bloodstream infection. Catheter insertion
is an unpleasant experience for patients and replacement may be unnecessary if the catheter remains functional and there are no signs
of inflammation or infection. Costs associated with routine replacement may be considerable. This is the third update of a review first
published in 2010.
Objectives
To assess the effects of removing peripheral intravenous catheters when clinically indicated compared with removing and re-siting the
catheter routinely.
Search methods
The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase
and CINAHL and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to
18 April 2018. We also undertook reference checking, and contacted researchers and manufacturers to identify additional studies.
Selection criteria
We included randomised controlled trials that compared routine removal of PIVC with removal only when clinically indicated, in
hospitalised or community-dwelling patients receiving continuous or intermittent infusions.
Data collection and analysis
Three review authors independently reviewed trials for inclusion, extracted data, and assessed risk of bias using Cochrane methods. We
used GRADE to assess the overall evidence certainty.
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Main results
This update contains two new trials, taking the total to nine included studies with 7412 participants. Eight trials were conducted in
acute hospitals and one in a community setting. We rated the overall certainty of evidence as moderate for most outcomes, due to
serious risk of bias for unblinded outcome assessment or imprecision, or both. Because outcome assessment was unblinded in all of the
trials, none met our criteria for high methodological quality.
Primary outcomes
Seven trials (7323 participants), assessed catheter-related bloodstream infection (CRBSI). There is no clear difference in the incidence
of CRBSI between the clinically indicated (1/3590) and routine change (2/3733) groups (risk ratio (RR) 0.61, 95% confidence interval
(CI) 0.08 to 4.68), low-certainty evidence (downgraded twice for serious imprecision).
All trials reported incidence of thrombophlebitis and we combined the results from seven of these in the analysis (7323 participants). We
excluded two studies in the meta-analysis because they contributed to high heterogeneity. There is no clear difference in the incidence
of thrombophlebitis whether catheters were changed according to clinical indication or routinely (RR 1.07, 95% CI 0.93 to 1.25;
clinically indicated 317/3590; 3-day change 307/3733, moderate-certainty evidence, downgraded once for serious risk of bias). The
result was unaffected by whether the infusion was continuous or intermittent. Six trials provided thrombophlebitis rates by number
of device days (32,709 device days). There is no clear difference between groups (RR 0.90, 95% CI 0.76 to 1.08; clinically indicated
248/17,251; 3-day change 236/15,458; moderate-certainty evidence, downgraded once for serious risk of bias).
One trial (3283 participants), assessed all-cause blood stream infection (BSI). We found no clear difference in the all-cause BSI rate
between the two groups (RR 0.47, 95% CI 0.15 to 1.53; clinically indicated: 4/1593 (0.02%); routine change 9/1690 (0.05%);
moderate-certainty evidence, downgraded one level for serious imprecision).
Three trials (4244 participants), investigated costs; clinically indicated removal probably reduces device-related costs by approximately
AUD 7.00 compared with routine removal (MD −6.96, 95% CI −9.05 to −4.86; moderate-certainty evidence, downgraded once for
serious risk of bias).
Secondary outcomes
Six trials assessed infiltration (7123 participants). Routine replacement probably reduces infiltration of fluid into surrounding tissues
compared with a clinically indicated change (RR 1.16 (95% CI 1.06 to 1.26; routine replacement 747/3638 (20.5%); clinically
indicated 834/3485 (23.9%); moderate-certainty evidence, downgraded once for serious risk of bias).
Meta-analysis of seven trials (7323 participants), found that rates of catheter failure due to blockage were probably lower in the routine-
replacement group compared to the clinically indicated group (RR 1.14, 95% CI 1.01 to 1.29; routine-replacement 519/3733 (13.9%);
clinically indicated 560/3590 (15.6%); moderate-certainty evidence, downgraded once for serious risk of bias).
Four studies (4606 participants), reported local infection rates. It is uncertain if there are differences between groups (RR 4.96, 95%
CI 0.24 to 102.98; clinically indicated 2/2260 (0.09%); routine replacement 0/2346 (0.0%); very low-certainty evidence, downgraded
one level for serious risk of bias and two levels for very serious imprecision).
One trial (3283 participants), found no clear difference in the incidence of mortality when clinically indicated removal was compared
with routine removal (RR 1.06, 95% CI 0.27 to 4.23; low-certainty evidence, downgraded two levels for very serious imprecision).
One small trial (198 participants) reported no clear difference in device-related pain between clinically indicated and routine removal
groups (MD −0.60, 95% CI −1.44 to 0.24; low-certainty evidence, downgraded one level for serious risk of bias and one level for
serious imprecision).
The pre-planned outcomes ’number of catheter re-sites per patient’, and ’satisfaction’ were not reported by any studies included in this
review.
Authors’ conclusions
There is moderate-certainty evidence of no clear difference in rates of CRBSI, thrombophlebitis, all-cause BSI, mortality and pain
between clinically indicated or routine replacement of PIVC. We are uncertain if local infection is reduced or increased when catheters
are changed when clinically indicated. There is moderate-certainty evidence that infiltration and catheter blockage is probably lower
when PIVC are changed routinely; and moderate-certainty evidence that clinically indicated removal probably reduces device-related
costs. The addition of two new trials for this update found no further evidence to support changing catheters every 72 to 96 hours.
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Healthcare organisations may consider changing to a policy whereby catheters are changed only if there is a clinical indication to do
so, for example, if there were signs of infection, blockage or infiltration. This would provide significant cost savings, spare patients
the unnecessary pain of routine re-sites in the absence of clinical indications and would reduce time spent by busy clinicians on this
intervention. To minimise PIVC-related complications, staff should inspect the insertion site at each shift change and remove the
catheter if signs of inflammation, infiltration, occlusion, infection or blockage are present, or if the catheter is no longer needed for
therapy.
P L A I N L A N G U A G E S U M M A R Y
Replacing a peripheral venous catheter when clinically indicated versus routine replacement
Review question
We reviewed the evidence about the effects of changing a catheter routinely (every three to four days) or changing the catheter only if
there were signs or symptoms of a problem with the catheter remaining in place.
Background
Most hospital patients receive fluids or medications via a peripheral intravenous catheter at some time during their hospital stay. An
intravenous catheter (also called an IV drip, an IV line or intravenous cannula) is a short, hollow tube placed in the vein to allow
administration of medications, fluids or nutrients directly into the bloodstream. These catheters are often replaced every three to four
days to try to prevent irritation of the vein or infection of the blood. However, replacing the catheter may cause discomfort to patients
and is quite costly. This is the third update of a review first published in 2010.
Study characteristics
In April 2018 we searched for randomised controlled trials (RCTs) that compared changing catheters every 72 to 96 hours (routine
change) with changing the catheter only if there were complications or therapy was complete. We measured catheter-related blood
stream infection, phlebitis and other problems associated with peripheral catheters, such as local infection and catheter blockage. We
included two new studies for this update, bringing the total to nine studies with 7412 participants.
Key results
We found no clear difference in rates of catheter-related blood stream infection, phlebitis (inflammation of the vein), blood stream
infection from any cause, local infection, mortality or pain. We are uncertain if local infection is reduced or increased when catheters
are changed when clinically indicated. Infiltration (fluid seeping into the tissue around the catheter) and catheter blockage (an inability
to infuse fluids or medication through the catheter), are probably reduced when catheters are changed routinely. Cost is reduced when
catheters are replaced when there was a clinical indication to do so. The pre-planned outcomes ’number of catheter re-sites per patient’,
and ’satisfaction’ were not reported by any studies included in the review.
Quality of the evidence
The overall quality of the evidence was judged to be moderate for most outcomes, which leaves us uncertain of our findings. The
uncertainty is largely due to outcomes, such as phlebitis, being assessed by people who were aware of the group allocation, which may
or may not affect their decision about whether a problem is present or absent.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Effects of clinically indicated replacement compared to routine change of peripheral intravenous catheters (PIVC)
Patient or population: any pat ient requiring a PIVC expected to remain in-situ for at least 3 days
Setting: hospital or community
Intervention: PIVC replaced if a clinical indicat ion is present
Comparison: changing the PIVC rout inely, according to a set t ime f rame (usually between 72-96 hours)





















There is no clear dif f er-
ence in the incidence of
catheter-related blood
stream infect ion. The
wide CI includes the
possibility of both in-
creased and decreased
infect ion. The true ef -
fect could range f rom
a 92% reduct ion to a
4.68 t imes increase in
the clinically indicated
group
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such as blood stream
infect ion was blinded;
only 2 trials reported
these outcomes. Most
outcomes were as-
sessed by clinicians or
researchers who were
aware of the group to
which the part icipant
belonged











There is no clear dif f er-
ence in the incidence
of phlebit is when as-
sessed correct ly (in-
cidence/ 1000 device
days) between the clin-
ically indicated and
rout ine-change groups.
The true ef fect could
range f rom a 24% re-
duct ion to an 8% in-
crease in the clinically
indicated group
15 per 1000 14 per 1000
(12 to 16)
All- cause blood stream
infection
(during hospitalisat ion)






There is no clear dif -
ference in all-cause
blood stream infec-
t ions between the clini-
cally indicated and rou-
t ine-change groups. Al-
though a large trial, only
Rickard 2012 assessed
this outcome. The as-




























































































































The mean cost in the
control group was AUD
51.02
The mean cost in the
intervent ion group was
AUD 44.14
MD






















probably leads to a
slight ly lower incidence
of inf ilt rat ion compared
to a clinically indicated
change











probably leads to a
slight ly lower incidence
of blockage compared
to a clinically indicated
change
139 per 1000 158 per 1000
(140 to 179)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MD: mean dif ference; PIVC: peripheral intravenous catheter; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect






















































































































2 Downgraded one level for serious risk of bias (no blind outcome assessment).
























































































































B A C K G R O U N D
Among hospitalised patients, vascular access is the most common
invasive procedure with 80% of hospital admissions involving an
average of two vascular access devices per patient (Hadaway 2012).
Peripheral intravenous (IV) access is associated with a pooled pro-
portion for phlebitis of 36% (Marsh 2018a), and a pooled pro-
portion catheter-related blood stream infection (CRBSI) rate of
less than 0.1% (Marsh 2018a). A number of current guidelines
have been updated to reflect findings from previous versions of this
systematic review (Webster 2015), recommending changing short
peripheral intravenous catheters (PIVC) when there is a clinical
indication to do so (Infusion Nurses Society 2011; Loveday 2014).
However, the influential Centers for Disease Control (CDC)
guidelines state that, “no recommendation is made regarding re-
placement of peripheral catheters in adults only when clinically in-
dicated” (p. 15, O’Grady 2011). In practice most hospitals already
exempt patients with poor veins from routine changes and, for
children, CDC guidelines have always recommended that PIVC
be replaced only when clinically indicated (O’Grady 2011). In re-
cent years, there have been improvements in catheter design and
composition, and more recent studies, including an earlier version
of this review (Webster 2015), indicate that the recommendation
may need to be revised. Based on level 1 evidence, the most recent
Infusion Nursing Standards of Practice in the USA and the epic3
National Evidence Based Guidelines in the UK recommend that
short PIVC should be replaced when clinically indicated, unless
the patient is receiving parenteral nutrition peripherally (Infusion
Nurses Society 2011; Loveday 2014). The projected five-year sav-
ings from implementing clinically indicated PIVC removal poli-
cies is USD 300 million and 1 million health-worker hours in the
USA alone (Tuffaha 2014a; Tuffaha 2014b).
Description of the condition
Catheter-related blood stream infection (CRBSI), defined as the
presence of bacteraemia originating from an intravenous (IV)
catheter, is a rare but severe outcome of IV catheterisation (Gahlot
2014). The infection occurs when bacteria track along the catheter
and enter the bloodstream. The bacterial source may be the pa-
tient’s own skin or that of a healthcare provider; CRBSI has an at-
tributable mortality rate of 12% to 25% (Maki 2006). Peripheral
vein infusion thrombophlebitis (phlebitis) is characterised by pain,
erythema (redness of the skin), swelling, and palpable thrombosis
of the cannulated vein (Monreal 1999). Diagnosis remains con-
troversial and a number of grading systems have been proposed,
although with limited validation testing performed (Ray-Barruel
2014). These include the Maddox scale (Maddox 1977), and
the Baxter scale (Panadero 2002), which rank infusion throm-
bophlebitis according to the severity of clinical signs and symp-
toms. The scales are limited because not all symptoms may be
present, or they may not always be present in the clusters de-
scribed in the scales. Consequently, many investigators define pe-
ripheral vein infusion thrombophlebitis based on two or more
of the following; pain, tenderness, warmth, erythema, swelling,
and a palpable cord (Maki 1991; Monreal 1999). More recently,
a new definition for phlebitis has been proposed, one based on
a more objective assessment of the insertion site (Rickard 2012).
Although the precise pathogenesis of thrombus formation remains
unclear, it is thought to be related to inflammation of the vein
wall. Studies have been unable to demonstrate a high correlation
between phlebitis and catheter infection and Maki has suggested
that phlebitis may primarily be a physical response (Maki 1991).
This suggestion was supported by Catney and colleagues when
investigating the aetiology of phlebitis; they found that drug ir-
ritation, size of catheter, and the person inserting the catheter
were all predictors of phlebitis (Catney 2001). Utrasonographic
imaging has demonstrated thrombus formation in two-thirds of
catheterised veins studied and it has been suggested that catheter
design may be implicated (Everitt 1997). Thus, possible causes
of phlebitis are mechanical irritation from the catheter and the
properties of the infusate or IV-administered medications, partic-
ularly flucloxacillin, which is associated with a two-fold increase
in phlebitis (Marsh 2018b).
Description of the intervention
The intervention under consideration is replacing an PIVC only
if there are clinical indications to do so. Clinical indications in-
clude blockage, pain, redness, infiltration, swelling, leakage, and
phlebitis, as well as when therapy is completed.
How the intervention might work
Each time a catheter is inserted, the patient’s skin integrity is
breached and a potential portal for pathogens is provided. For ex-
ample, a significant relationship was found between the number
of times PIVC were inserted and phlebitis in a study of 568 IV
sites (Uslusoy 2008). Consequently, it may be prudent to limit the
frequency of PIVC replacements if there is no clinical reason to
do so. There is some support for this approach from observational
studies that have compared outcomes between catheters remain-
ing in situ for varying periods. In an adequately powered observa-
tional study, which included participants from medical wards and
intensive care units, the investigators were unable to demonstrate
any increased risk of phlebitis beyond the second day (Bregenzer
1998). Similarly, in a retrospective study of 784 IV catheter starts,
the rate of phlebitis on days one and two was 11.5%, dropping
to 3.9% by day four (Homer 1998). The authors concluded that,
“there appeared to be less risk in continuing therapy beyond the
third day than re-starting the therapy” (pp 304). Catney 2001 also
failed to demonstrate any increase in phlebitis rates with the pas-
sage of time, with failure rates being less at 144 hours (1.9%) than
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at 72 hours (2.5%) (Catney 2001). Similarly, in a prospective in-
vestigation of 305 PIVC there were 10 cases of infusion phlebitis
amongst patients who had their catheter in situ for fewer than
72 hours whereas none were reported in patients where the dwell
time was longer (White 2001). In the same study, there were three
cases of post-infusion phlebitis; these all occurred amongst par-
ticipants whose PIVC had been in place for fewer than 72 hours.
Even among a high-risk population of oncology and infectious
diseases patients, phlebitis rates were no different when length of
cannulation was dichotomised to three days or fewer and more
than three days (Cornely 2002).
Why it is important to do this review
These observational studies and previous versions of our Cochrane
Review (Webster 2010; Webster 2013; Webster 2015), create un-
certainty around the US Centers for Disease Control (CDC)
guidelines relating to PIVC management, which states that clin-
ically indicated replacement in adults is an “unresolved issue”
(O’Grady 2011). The recommendation referenced an earlier ver-
sion of this review (Webster 2010), which showed ’no difference’
between the two approaches to PIVC replacement. As long as dis-
crepancies exist between the CDC recommendations, often seen
as the gold standard, and other international guidelines, updating
this review with contemporary evidence is important. Particularly
when ’choosing wisely’ commentators find that “routine replace-
ment should be considered a thing that we do for no reason” (Patel
2017). The review is also important because insertion of a PIVC
may be painful, especially when placed in the hand or wrist, with
an average score of 4.5 on a 10-point pain scale (Tan 2016), so pre-
venting unnecessary replacements may reduce a potentially trau-
matic experience for patients. Additionally, routine replacement
has significant cost implications for the facility. Routine replace-
ment costs approximately AUD 7 more per patient compared with
clinically indicated replacement (Tuffaha 2014a). With an esti-
mated two billion PIVC used globally each year (Rickard 2018),
there is a clear need to provide direction for clinicians and admin-
istrators by systematically searching for and appraising relevant
studies to add to the review.
O B J E C T I V E S
To assess the effects of removing peripheral intravenous catheters
when clinically indicated compared with removing and re-siting
the catheters routinely.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials (RCTs) comparing
routine removal of PIVC with removal only when clinically indi-
cated. Cross-over trials were not eligible for inclusion.
Types of participants
We included any patient requiring a PIVC to be in situ for at least
three days for the administration of intermittent or continuous
therapy (this may include patients in hospitals, nursing homes,
or in community settings). We excluded participants receiving
parenteral fluids.
Types of interventions
We included short PIVC made from any type of material (for
example metal, plastic); non-coated or coated with any type of
product (for example antibiotic, anticoagulant); or covered by any
type of dressing (for example gauze, clear, occlusive). We included
any duration of time before routine replacement versus clinically
indicated replacement. We excluded midline catheters and long
peripheral catheters.
Types of outcome measures
Primary outcomes
• Catheter-related blood stream infection (CRBSI, defined as
a positive blood culture from a peripheral vein; clinical signs of
infection; no other apparent source for the bloodstream infection
except the IV catheter; and colonised IV catheter tip culture with
the same organism as identified in the blood)
• Thrombophlebitis (using any definition identified by the
trial author)
• All-cause bloodstream infection (BSI, defined as a any
positive blood culture drawn from a peripheral vein while an IV
catheter is in situ or for 48 hours after removal)
• Cost (in terms of materials and labour associated with IV
catheter-related insertion)
Secondary outcomes
• Infiltration (defined as permeation of IV fluid into the
interstitial compartment, causing swelling of the tissue around
the site of the catheter)
• Catheter occlusion or blockage (identified by the inability
to infuse fluids)
• Number of catheter re-sites per participant
• Local infection (using any definition identified by the trial
author)
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• Mortality
• Pain during infusion (measured by any validated pain
assessment scale)
• Satisfaction (measured by any validated satisfaction scale)
Search methods for identification of studies
There was no restriction on language. If foreign language studies
had been found, we intended to seek initial translation of abstracts
for the application of the inclusion and exclusion criteria. Where
necessary, the methods, results, and discussion sections would have
been translated for inclusion in the review.
Electronic searches
The Cochrane Vascular Information Specialist (CIS) conducted
systematic searches of the following databases for RCTs without
language, publication year or publication status restrictions:
• the Cochrane Vascular Specialised Register via the Cochrane
Register of Studies (CRS-Web searched on 18 April 2018);
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 3) via Cochrane Register of Studies
Online;
• MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MEDLINE®
Daily and Ovid MEDLINE®) (searched from 1 January 2017 to
18 April 2018);
• Embase Ovid (searched from 1 January 2017 to 18 April
2018);
• CINAHL Ebsco (searched from 1 January 2017 to 18 April
2018);
• AMED Ovid (searched from 1 January 2017 to 18 April
2018).
The Information Specialist modelled search strategies for other
databases on the search strategy designed for CENTRAL. Where
appropriate, they were combined with adaptations of the highly
sensitive search strategy designed by the Cochrane Collaboration
for identifying RCTs and controlled clinical trials (as described
in the Cochrane Handbook for Systematic Reviews of Interventions
Chapter 6, Lefebvre 2011). Search strategies for major databases
are provided in Appendix 1.
The Information Specialist searched the following trials registries
on 18 April 2018:
• the World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch);
• ClinicalTrials.gov ( clinicaltrials.gov/).
Searching other resources
We contacted researchers and manufacturers in order to obtain
any unpublished data. Reference lists of potentially useful articles
were also searched.
We also searched the following clinical trials registries:
• ClinicalTrials.gov ( clinicaltrials.gov/; 12 July 2018), using
the terms peripheral and intravenous and catheter and routine;
• World Health Organization International Clinical Trials
Registry Platform (ICTRP; apps.who.int/trialsearch/) (12 July
2018) using the terms peripheral and intravenous and catheter;
• Australian and New Zealand Clinical Trials Registry
(ANZCTR; 12 July 2018), using the terms peripheral and
intravenous and catheter.
Data collection and analysis
Selection of studies
Two review authors independently reviewed titles and abstracts
identified through the search process (JW, NM). We retrieved full
reports of all potentially relevant trials for further assessment of
eligibility based on the inclusion criteria. If we excluded any full
texts, we recorded the reasons. We completed a PRISMA flow
chart (Liberati 2009; Figure 1), to summarise the selection process.
As the review authors were also the investigators on some of the
included trials, we allocated assessment to a review author who was
not an investigator (former author KN). We settled differences of
opinion by consensus or referral to a third review author. There
was no blinding of authorship.
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Figure 1. Study flow diagram
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Data extraction and management
Following Cochrane Vascular recommendations, two review au-
thors (two of JW, CR, or SO) independently extracted data to
a pre-tested data extraction form. We resolved disagreements by
discussion and, where necessary, by a involving third review au-
thor. We contacted authors of published and unpublished trials
for additional information.
We extracted the following main sets of data from each included
study:
• lead author, date;
• study participant inclusion criteria;
• country where the research was conducted;
• participants’ gender and age;
• study design, randomisation processes, allocation
concealment;
• intervention descriptions;
• intervention setting (hospital, home, residential aged care
facilities);
• numbers of participants in each trial arm, withdrawals and
dropouts;
• outcome measures, time(s) at which outcomes were
assessed;
• funding source;
• ethics approval and consent;
• prospective registration on a clinical trials registry.
The first review author (JW) entered the data into Review Manager
5, with another review author (NM) checking data entry accuracy
(Review Manager 2014).
Assessment of risk of bias in included studies
Two review authors (two of JW, CR, SO, NM) independently
assessed the included studies using the Cochrane Collaboration
tool for assessing risk of bias (Higgins 2017). This tool addresses
six specific domains, namely sequence generation, allocation con-
cealment, blinding, incomplete outcome data, selective outcome
reporting, and other issues (for example extreme baseline imbal-
ance). We resolved any disagreements between review authors by
consensus or referral to a third review author. We contacted the
investigators of included trials to resolve any ambiguities.
Measures of treatment effect
For individual trials, effect measures for categorical outcomes in-
cluded risk ratio (RR) with its 95% confidence interval (CI). For
statistically significant effects, we calculated the number needed
to treat for an additional beneficial outcome (NNTB) or num-
ber needed to treat for an additional harmful outcome (NNTH).
For continuous outcomes the effect measure we used was mean
difference (MD) or, if the scale of measurement differed across
trials, standardised mean difference (SMD), each with its 95%
CI. For any meta-analyses (see below), for categorical outcomes
we calculated the typical estimates of RR with their 95% CI; and
for continuous outcomes we calculated the mean difference (MD)
or a summary estimate for standardised mean difference (SMD),
each with its 95% CI. We analysed data using the Cochrane Col-
laboration’s Review Manager 5 software (Review Manager 2014).
’Summary of findings’ tables
To assess the overall body of evidence, we developed ’Summary









We assessed the certainty of the body of evidence against five prin-
ciple domains: 1) limitations in design and implementation; 2)
indirectness of evidence or generalisability of findings; 3) inconsis-
tency of results, for example unexplained heterogeneity and incon-
sistent findings; 4) imprecision of results where confidence inter-
vals were wide; and 5) other potential biases, for example publica-
tion bias or high manufacturer involvement (Schünemann 2017).
We downgraded the evidence from ’high certainty’ by one level
for serious risk of bias or by two for very serious risk of bias.
Unit of analysis issues
Unit of analysis issues may arise in catheter trials when the par-
ticipant is randomised but the number of outcomes are reported
per catheter. We resolved this issue by using the participant as the
unit of analysis if the number of catheters and number of partic-
ipants were similar (assuming one catheter per individual). The
more difficult challenge is where studies randomise at the partic-
ipant level, use the allocated intervention on multiple catheters
per participant, and then analyse outcomes per catheter. Such ap-
proaches should be treated as cluster trials. If a cluster trial had
been correctly analysed, we planned to include effect estimates in
any meta-analysis using the generic inverse methods in Review
Manager 5 (Review Manager 2014).
Comparing longer and shorter PIVC dwell times on crude inci-
dence of complications is also problematic; this does not take into
12Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
account the cumulative daily risk inherent with peripheral intra-
venous device (IVD) use. There is clearly a ‘per day risk’ that is
present, and grows with each day of intravascular treatment, re-
gardless of how many IVDs are used over the period of therapy.
This cannot be extrapolated to mean that restricting (removing)
individual IVDs will reduce overall risk. That is, an IVD in situ
for seven days has seven days of exposure to risk compared with an
IVD in use for only three days, but if the patient requires therapy
for seven days in total then using multiple catheters over the period
may not reduce risk but merely divide the same risk between mul-
tiple catheters. Appropriate time comparisons need to be made
using statistics such as Kaplan-Meier analysis, logistic regression,
or Cox proportional models. It is vital that the participant is used
as the unit of measurement (denominator for comparison), not
the IVD. If a patient requires therapy, for example for five days,
they may have one catheter used for the entire time or alternately
multiple IVDs used over the five days. If the multiple catheters
are viewed independently they may appear to have lower risk per
catheter but the total risk for the patient over the five days may
be the same. We dealt with this by only including studies where
data were available per participant rather than per catheter. Where
data were not originally analysed in this format we contacted the
investigators (for example Van Donk 2009), to get these data. For
comparison, we also included an analysis of phlebitis per catheter
days where this information was available.
Where a cluster-randomised trial had been included but incor-
rectly analysed, we planned to record the unit of analysis issue in
our ’Risk of Bias’ assessment. If possible, we planned to approx-
imate the correct analyses based on guidance from the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
That is, we calculated the ’design effect’ by using the formula 1+
(M-1) ICC where M is the average size of each cluster, We did
identify one cluster-randomised trial, the results of which did not
appear to have been adjusted (Xu 2017). For this trial, we were
unable to identify an external intracluster correlation coefficient
(ICC), so used an estimate of 0.02 and calculated the average clus-
ter size to be 58.9.
Dealing with missing data
If any outcome data remained missing despite our attempts to
obtain complete outcome data from trial authors, we assessed the
risk of bias of the missing data and decided if the missing data were
at ’low’ or ’high’ risk of bias according to our ’Risk of bias’ criteria
(Higgins 2017). If we considered data to be missing at random,
we analysed the available information. If standard deviations were
missing, we planned to impute them from other studies or, where
possible, compute them from standard errors using the formula
SD = SE X
√
N where these were available (Higgins 2011b).
Assessment of heterogeneity
We explored clinical heterogeneity by examining potentially influ-
ential factors, for example, intervention dwell time, care setting,
or participant characteristics. We assessed statistical heterogeneity
using the Chi 2 test (considering P < 0.10 to represent significant
heterogeneity), along with the I2 statistic (Higgins 2003), which
examines the percentage of total variation across studies due to
heterogeneity rather than to chance. We planned to explore po-
tential causes of moderate to significant heterogeneity (I2 > 30%)
and use a random-effects approach to the analyses (Deeks 2017).
Assessment of reporting biases
We assessed reporting bias using guidelines in the Cochrane Hand-
book for Systematic Reviews of Interventions (Sterne 2017). Report-
ing bias occurs when reports of research results are affected by the
type and direction of results. We assessed reporting bias in each
study as part of our ’Risk of Bias’ evaluation. If sufficient study
data had been available for individual outcomes (> 10 trials), we
would have developed funnel plots and inspected them for evi-
dence of publication bias.
Data synthesis
Where clinical and statistical heterogeneity was low, we pooled
results of comparable trials using a fixed-effect model, and re-
ported the pooled estimate together with its 95% CI. Otherwise,
we used a random-effects model for our meta-analytic approach.
In cases where clinical heterogeneity between studies was similar
but heterogeneity was high, we planned to meta-analyse results
and attempt to provide an explanation for the heterogeneity. We
conducted a narrative review of eligible studies where statistical
synthesis of data from more than one study was not possible or
considered not appropriate.
Subgroup analysis and investigation of heterogeneity
We planned to analyse potential sources of heterogeneity using the
following subgroup analyses.
• Type of randomisation (truly randomised versus not
reported)
• Concealment of allocation (adequate versus not reported)
• Blinding (participants and clinicians blinded versus open-
label)
• Statement of withdrawals and losses to follow-up in each
group (stated versus not stated)
• Intermittent versus continuous infusion
Sensitivity analysis
We planned to perform sensitivity analyses to explore the effect of
the following criteria:
• Concealment of allocation
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• Size of studies (< 100 participants versus at least 100
participants)
• Duration of follow-up
• Unpublished studies
R E S U L T S
Description of studies
Results of the search
See Figure 1.
For this update, we identified 4541 unique records through our
electronic search. After reading titles and abstracts there were two
additional citations which we considered potentially relevant (
Chin 2018; Xu 2017). Chin 2018 was an abstract of an Australian
trial in newborn infants with insufficient information in the report
to consider inclusion. We contacted the author, asking for further
study details but have had no response; we have placed a reference
to the report in the Studies awaiting classification section of the
review. We retrieved the full text of the second study and have
included it in this update (Xu 2017). We have also included results
from an unpublished study, which we were aware of through our
network of intravascular device researchers (Vendramim 2018).
We did not find any additional trials in our search of trials registries.
Included studies
Nine RCTs, involving a total of 7392 participants met the inclu-
sion criteria (Barker 2004; Nishanth 2009; Rickard 2010; Rickard
2012; Van Donk 2009; Vendramim 2018; Webster 2007; Webster
2008; Xu 2017), see Characteristics of included studies for de-
tails. Individual trial sizes ranged between 42 and 3283 partic-
ipants. Five trials were carried out in Australia (Rickard 2010;
Rickard 2012; Van Donk 2009; Webster 2007; Webster 2008),
and one each was carried out in Brazil (Vendramim 2018), China
(Xu 2017), England (UK (Barker 2004)), and India (Nishanth
2009). Five of the trials were conducted in single-centre, acute
inpatient settings (Barker 2004; Nishanth 2009; Rickard 2010;
Webster 2007; Webster 2008), two were multicentred trials in
large tertiary hospitals - one in Australia (Rickard 2012) and one
in Brazil (Vendramim 2018); the Chinese trial was a cluster trial,
which randomised 20 hospital wards (Xu 2017); and one trial was
undertaken in a community setting (Van Donk 2009).
In eight trials (Barker 2004; Nishanth 2009; Rickard 2010;
Rickard 2012; Vendramim 2018; Webster 2007; Webster 2008;
Xu 2017), patients were included if they were receiving either con-
tinuous infusions or intermittent infusions for medication ther-
apy, whereas the catheters in the Van Donk 2009 trial were used
for intermittent medication therapy only. In seven trials (Rickard
2010; Rickard 2012; Van Donk 2009; Vendramim 2018; Webster
2007; Webster 2008; Xu 2017), the comparison was between rou-
tine care (planned 72- to 96-hour changes) and clinically indi-
cated changes. Barker 2004 and Nishanth 2009 compared 48-
hour changes with removal for clinical indications such as pain,
catheter dislodgement, or phlebitis.
Xu 2017; Rickard 2010 and Rickard 2012 defined CRBSI by us-
ing the CDC definition: a positive blood culture from a peripheral
vein; clinical signs of infection; no other apparent source for the
bloodstream infection except the IV catheter (in situ within 48
hours of the bloodstream infection); and a colonised IV catheter tip
with the same organism identified in the blood (O’Grady 2011).
In the Webster 2007 and Webster 2008 trials CRBSI was based
on the isolation of a phenotypically identical organism from a
catheter segment and a blood culture. None of the other trials
provided definitions of CRBSI. Seven of the trials used a stan-
dard definition of two or more of the following: pain, warmth,
erythema, swelling, or a palpable cord to define phlebitis (Barker
2004; Rickard 2010; Rickard 2012; Vendramim 2018; Webster
2007; Webster 2008; Xu 2017). Barker 2004 and Nishanth 2009
further classified phlebitis as either mild, moderate, or severe, de-
pending on the area of erythema (Barker 2004), or on the num-
ber of symptoms (Nishanth 2009). Van Donk 2009 included the
same symptoms as other trials but scored them as either one or two
depending on the severity. A score of two or more was classified
as phlebitis, consequently a participant may have had only one
symptom, for example pain, to receive a positive diagnosis.
Nishanth 2009; Rickard 2010; Rickard 2012; Van Donk 2009;
Vendramim 2018; Webster 2007; Webster 2008; and Xu 2017
reported power calculations but Barker 2004 did not. All of the
studies had institutional ethical approval.
Excluded studies
We did not exclude any new studies in this update. The table
Characteristics of excluded studies contains the reasons for exclud-
ing nine trials (Arnold 1977; Cobb 1992; Eyer 1990; Haddad
2006; Kerin 1991; May 1996; Nakae 2010; Panadero 2002;
Rijnders 2004). In summary, two were very small studies involv-
ing the administration of peripheral parenteral nutrition. Neither
trial compared straightforward routine replacement with clinically
indicated removal (Kerin 1991; May 1996). Panadero 2002 com-
pared one group that used the same catheter both intraoperatively
and postoperatively with a group using two catheters, one during
surgery and one postoperatively. Haddad 2006 compared 72-hour
changes with 96-hour changes, and Cobb 1992; Eyer 1990; Nakae
2010; and Rijnders 2004 involved central venous catheters. The
other excluded study was not an RCT (Arnold 1977).
Risk of bias in included studies
See individual ’Risk of bias’ tables and Figure 2; Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Generation of random allocation sequence
Eight of the nine investigators reported that they used a computer-
based sequence generator (Barker 2004; Nishanth 2009; Rickard
2010; Rickard 2012; Van Donk 2009; Vendramim 2018; Webster
2007; Webster 2008). Xu 2017 used a ’coin toss’ to generate the
random sequence. All studies were at low risk of bias except for
Nishanth 2009, where it was unclear how they had generated the
sequence.
Allocation concealment
Barker 2004; Nishanth 2009 and Van Donk 2009 used sealed
envelopes for allocation concealment. Vendramim 2018 provided
each ward with a sequentially numbered, randomised list. A coin
toss in the Xu 2017 trial concealed allocation until randomisa-
tion. The remaining four trials used a central telephone or com-
puter-based service (Rickard 2010; Rickard 2012; Webster 2007;
Webster 2008). All studies were at low risk of bias except for
Nishanth 2009, which was at high risk due to the investigators
being responsible for allocation.
Blinding
It was not possible to blind either the participants or the healthcare
providers in any of the trials but we did not believe that outcomes
would be affected by this knowledge so we judged all trials to be
at low risk of performance bias, except for Barker 2004 which we
considered to be at high risk of bias because the investigator was
involved in all stages of the study.
Outcome assessment
The chief investigator was directly involved in assessing outcomes
in Barker 2004 and Nishanth 2009. In the Van Donk 2009;
Vendramim 2018; Webster 2007 and Webster 2008 trials, nurses
caring for the participant or a dedicated IV service nurse made
the assessment. None of the nurses were blinded to the group
allocation but nor were any of them associated with the trial. In
Rickard 2010; Rickard 2012 and Xu 2017, a dedicated research
nurse, who was also aware of the allocation, undertook outcome
assessment. Because outcome assessment could not be blinded
(except for CRBSI), we classified all trials as high risk of bias.
Incomplete outcome data
Barker 2004 did not provide a flow chart, so the numbers screened
and eligible were unclear, nor did they report any dropouts. There
was also an imbalance in the number of participants reported by
group in this trial, which may indicate either a failure in the ran-
domisation process in such a small trial or incomplete reporting.
They did not report the number of protocol violations by group,
and we judged Barker 2004 to be at high risk of attrition bias.
The remaining eight studies were at low risk of bias as there was
complete reporting and all provided a flow of participants through
each stage and used intention-to-treat analysis (Nishanth 2009;
Rickard 2010; Rickard 2012; Van Donk 2009; Vendramim 2018;
Webster 2007; Webster 2008; Xu 2017). Nishanth 2009 did not
report any protocol violations in the trial. In the Van Donk 2009;
Vendramim 2018; Webster 2007; Webster 2008; and Xu 2017
trials, between 7% and approximately one third of the participants
had protocol violations. Primarily, violations were in the routine
replacement groups, where catheters were not replaced within the
specified time period, reflecting day to day clinical practice.
Selective reporting
All studies were at low risk of reporting bias. Study protocols were
available for seven trials and reporting followed pre-planned anal-
yses (Rickard 2010; Rickard 2012; Van Donk 2009; Vendramim
2018; Webster 2007; Webster 2008; Xu 2017). Barker 2004 had
only one outcome (phlebitis) and Nishanth 2009 reported on out-
comes expected in this type of trial.
Other potential sources of bias
Five studies were at low risk of other bias (Rickard 2012; Van
Donk 2009; Vendramim 2018; Webster 2007; Webster 2008).
Barker 2004 used two definitions of phlebitis, one of which stated
that two symptoms were necessary; yet it appears that they diag-
nosed erythema alone as phlebitis, with severity based on the area
of inflammation; which leads to an assessment of high risk for
other bias. The extreme results in Nishanth 2009, where 100% of
participants in the clinically indicated group developed phlebitis
compared with 9% in the two-day change group, suggests that
chance or other unknown bias affected results in this small trial,
to which we also gave a high-risk judgement. Two studies were at
unclear risk of bias (Rickard 2010; Xu 2017). The Xu 2017 clus-
ter-randomised trial analysed by individual not cluster; and signif-
icantly more participants in the routine-change group received IV
antibiotics compared to the clinically indicated group in Rickard
2010.
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Effects of interventions
See: Summary of findings for the main comparison Effects of
clinically-indicated replacement compared to routine change of
peripheral intravenous catheters
Routine changes versus clinically indicated changes
Catheter-related bloodstream infection (Analysis 1.1)
Seven trials (7323 participants) assessed catheter-related blood-
stream infection (CRBSI; Rickard 2010; Rickard 2012; Van Donk
2009; Vendramim 2018; Webster 2007; Webster 2008; Xu 2017).
There were no reported CRBSIs in five of these trials (Rickard
2010; Van Donk 2009; Vendramim 2018; Webster 2007; Xu
2017). There is no clear difference in the incidence of CRBSI
between the clinically indicated (1/3590) and routine-change (2/
3733) groups. The RR was 0.61 but the confidence intervals (CI)
were wide, creating uncertainty around the estimate (95% CI 0.08
to 4.68; Figure 4; Analysis 1.1). We judged the evidence as low
certainty, as we downgraded two levels for serious imprecision.
Figure 4. Forest plot of comparison 1, clinically indicated versus routine change, outcome: 1.1 Catheter-
related bloodstream infection
Thrombophlebitis (Analysis 1.2 and Analysis 1.3)
All of the included studies reported incidence of phlebitis; the
initial analysis was based on 7412 participants. When results of
all trials were combined, heterogeneity was 65%. Consequently,
we conducted a sensitivity analysis and removed the two trials
with fewer than 100 participants (combined total n = 89), both of
which used a two-day replacement schedule and reported extreme
results (Barker 2004; Nishanth 2009). Removing the two trials
eliminated the heterogeneity (I2 = 0). We combined data from the
remaining seven studies, with 7323 participants (Rickard 2010;
Rickard 2012; Van Donk 2009; Vendramim 2018; Webster 2007;
Webster 2008; Xu 2017). There was no clear difference in this
outcome, whether catheters were changed according to clinical
indications or routinely (RR 1.07, 95% CI 0.93 to 1.25; clinically
indicated 317/3590; 3-day change 307/3733; moderate-certainty
evidence, downgraded once for serious risk of bias (no blinding of
outcome assessment in any of the trials)). The result was unaffected
by whether the infusion was continuous or intermittent (Analysis
1.2; Figure 5).
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Figure 5. Forest plot of comparison 1, clinically indicated versus routine change, outcome: 1.2 Phlebitis
In the two trials using a two-day replacement schedule com-
pared with clinically indicated changes (Barker 2004; Nishanth
2009), heterogeneity was over 60% so we did not combine re-
sults. In the first of these two trials, Barker 2004 reported that 11/
26 (42.3%) participants in the clinically indicated group devel-
oped phlebitis compared with 1/21 (4.8%) in the two-day change
group. Nishanth 2009 diagnosed all of the participants in the clin-
ically indicated group (21/21; 100.0%) with phlebitis and 2/21
(9.5%) in the two-day group. We judged the evidence from these
two trials to be very low certainty, downgraded two levels for very
serious risk of bias and two levels for very serious imprecision.
Six of the trials provided phlebitis rates by number of device days
(Rickard 2010; Rickard 2012; Van Donk 2009; Vendramim 2018;
Webster 2007; Webster 2008), but again, there is no clear differ-
ence between groups for this outcome (RR 0.90, 95% CI 0.76 to
1.08; clinically indicated 248/17,251; 3-day change 236/15,458;
moderate-certainty evidence, downgraded once for serious risk of
bias (no blind outcome assessment in any of the trials); Analysis
1.3; Figure 6).
Figure 6. Forest plot of comparison 1 clinically indicated versus routine change, outcome: 1.3 Phlebitis per
device days
All-cause bloodstream infection (Analysis 1.4)
One trial assessed this outcome (Rickard 2012). We found no clear
difference in the all-cause bloodstream infection rate between the
two groups (RR 0.47, 95% CI 0.15 to 1.53; clinically indicated:
4/1593 (0.02%); routine change 9/1690 (0.05%)). We judged the
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evidence as moderate certainty, downgraded one level for serious
imprecision (Analysis 1.4).
Cost (Analysis 1.5)
Three trials (4244 participants) measured this outcome (Rickard
2012; Webster 2007; Webster 2008). Device-related costs were
measured in Australian dollars (AUD). Clinically indicated re-
moval probably reduces device-related costs by approximately
AUD 7.00 per participant compared with routine removal (MD
−6.96, 95% CI −9.05 to −4.86; moderate-certainty evidence,
downgraded once for serious risk of bias (no blind outcome as-
sessment in any of the trials); Analysis 1.5).
Infiltration (Analysis 1.6)
A total of six trials assessed infiltration in 7123 participants
(Rickard 2010; Rickard 2012; Vendramim 2018; Webster 2007;
Webster 2008; Xu 2017). Routine replacement probably reduces
infiltration of fluid into surrounding tissues (747/3638; 20.5%)
compared with the clinically indicated group (834/3485; 23.9%).
The RR was 1.16 (95% CI 1.06 to 1.26); moderate-certainty ev-
idence, downgraded once for serious risk of bias (no blinding of
outcome assessment in any of the trials; Analysis 1.6).
Catheter occlusion/blockage (Analysis 1.7)
We included seven of the nine trials, reporting on 7323 partici-
pants, in this analysis (Rickard 2010; Rickard 2012; Van Donk
2009; Vendramim 2018; Webster 2007; Webster 2008; Xu 2017).
Rates of catheter failure due to blockage were probably lower in the
routine-replacement group compared to the clinically indicated
group (RR 1.14, 95% CI 1.02 to 1.27; routine-replacement group
519/3733 (13.9%); clinically indicated group 560/3590 (15.6%);
Analysis 1.7). We judged the evidence as moderate certainty, as we
downgraded once for serious risk of bias (no blinding of outcome
assessment in any of the trials).
Local infection (Analysis 1.8)
Among the four trials measuring local infection (Rickard 2010;
Rickard 2012; Webster 2007; Webster 2008), it is uncertain if
there are differences in local infection rates between groups (RR
4.96, 95% CI 0.24 to 102.98; clinically indicated 2/2260 (0.09%);
routine replacement 0/2346 (0.0%); very-low-certainty evidence,
downgraded one level for serious risk of bias (no blinding of out-
come assessment in any of the trials) and two levels for very serious
imprecision (Analysis 1.8)).
Mortality (Analysis 1.9)
One trial reported this outcome (Rickard 2012). In the clini-
cally indicated group 4/1593 (0.25%) died compared with 4/1690
(0.24%) in the routine-replacement group (RR 1.06, 95% CI 0.27
to 4.23). We judged the evidence as low certainty, downgraded
two levels for very serious imprecision (Analysis 1.9).
Pain during infusion (Analysis 1.10)
Vendramim 2018 (198 participants), measured pain on an 11-
point scale (0 to 10), where higher scores represented higher levels
of pain. There was no clear difference in device-related pain be-
tween clinically indicated and routine-removal groups. The mean
pain score in the clinically indicated group was 4.6 (SD 3.0), com-
pared with 5.2 (SD 3.0), in the routine replacement group (MD
−0.60, 95% CI −1.44 to 0.24; low-certainty evidence, down-
graded one level for serious risk of bias (no blinding of outcome
assessment in any of the trials) and one-level for serious impreci-
sion; Analysis 1.10).
The pre-planned outcomes ’number of catheter re-sites per pa-
tient’, and ’satisfaction’ were not reported by studies included in
the review.
Subgroup and sensitivity analysis
We planned to conduct subgroup analyses on 1) Type of randomi-
sation (truly randomised versus not reported); 2) Concealment
of allocation (adequate versus not reported) and; 3) Statement of
withdrawals and losses to follow-up in each group (stated versus
not stated). However, there were too few studies in these subgroups
to make any meaningful comparisons. Similarly, blinding was not
possible in any of the studies. We did not conduct any of our pre-
planned sensitivity analyses (except size of studies for the outcome
’phlebitis’), for similar reasons.
D I S C U S S I O N
Summary of main results
This systematic review analysed catheter-related bloodstream in-
fection (CRBSI), phlebitis, other reasons for catheter failure, and
cost with the intention of comparing routine catheter changes (at
between two and four days) with replacing the catheter only if
clinical signs warranting removal or replacement were apparent.
This update, which added a further two trials, confirms findings
from the previous version of this review (Webster 2015). The pri-
mary outcomes suggest that patients are not adversely affected if
the catheter is changed based on clinical indications rather than
routinely. The rate of catheter-related bloodstream infection was
similar in both groups, between 0.03% and 0.05%, and compara-
ble to that previously reported in prospective studies (Maki 2006).
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Because the incidence of peripheral intravenous (IV) CRBSI is
very low, mounting a trial with sufficient power to show differ-
ences in CRBSI between catheters removed routinely or by clin-
ical indication would be prohibitive. There is no clear difference
in the phlebitis rate between groups whether rates are reported by
the incidence per participant or by 1000 device days, which is a
more clinically useful measure. Most cases of phlebitis are mild
in nature, requiring no treatment or only removal of the catheter.
There was no indication in our review that phlebitis was a precur-
sor to bloodstream infection.
Catheter failure due to blockage was more frequent in the clini-
cally indicated group. This could be expected; all catheters will fail
eventually and will need to be replaced if treatment is ongoing.
The outcome is not clinically meaningful, it is simply an indi-
cator of the longer dwell times in the clinically indicated group.
Since the ‘treatment’ for a blocked catheter is replacement of the
catheter, it would not be of any benefit to the patient to replace
the catheter earlier since it would not reduce the need for replace-
ment, and would instead increase the chance of re-cannulation.
Many catheters do not fail over the course of IV treatment, even
with extended dwell times.
Cost was less, around AUD 7.00 per participant, in the clinically
indicated group. This result was based on three studies and results
were consistent and intuitively logical (fewer catheters, less clin-
ician time and equipment). Although, this is a seemingly small
amount, it corresponds to approximately 11% of catheter-related
expenditure, which may represent a considerable saving to organ-
isations with high use of peripheral intravenous catheters (PIVC).
Overall completeness and applicability of
evidence
Trials included in this systematic review directly addressed the re-
view question and we were able to conduct a number of meta-anal-
yses. Apart from Barker 2004 and Nishanth 2009, results from the
other seven trials were quite similar, providing useful external va-
lidity. For example, participants were representative of those usu-
ally managed in healthcare, including patients in both acute and
community settings. Additionally, measured outcomes were those
important to clinicians and patients. It has been suggested that in-
sertion and management by an IV team may explain the inefficacy
of routine replacement to prevent complications (Maki 2008), yet
we saw no effect in trials that had significant numbers inserted by
an IV team (Webster 2007; Webster 2008), or trials where inser-
tion was by the general medical and nursing staff (Rickard 2010;
Rickard 2012), and none of the trials involved research nurses or
IV teams providing post-insertion care of catheters. In all of the
trials, except for Barker 2004 and Nishanth 2009, standard guide-
lines were followed for the control group; that is, catheters were
changed at between 72 and 96 hours, reflecting usual care. Barker
2004 and Nishanth 2009 changed catheters every 48 hours. Only
Rickard 2012 was powered to report on phlebitis alone, and some
of the trials were very small. For example, the studies that showed
statistically lower phlebitis rates in the clinically indicated group
(Barker 2004; Nishanth 2009), involved just 47 and 42 partic-
ipants respectively and showed differences between the control
and intervention groups that were quite dissimilar to all of the
other studies. Consequently, results of these two trials should be
interpreted with caution, particularly results from Nishanth 2009,
where all participants in the clinically indicated group developed
phlebitis compared with none in the two-day change group. It
seems unlikely that these results would have occurred by chance
but correspondence with trial authors shed no further light on
these extreme results. There are no other published papers show-
ing phlebitis rates of 100%.
Five of the nine included trials were conducted in Australia; this
imbalance is difficult to understand but the two additional stud-
ies, one from China (Xu 2017), and one from Brazil (Vendramim
2018), provide added diversity to the evidence and increase exter-
nal validity. It would be useful to see similar studies from other
healthcare settings to test the robustness of results from this review.
Only Vendramim 2018 assessed levels of pain, and none of the
trials measured device-related satisfaction or number of catheter
re-sites per participant. These outcomes would be a useful addition
to any future trial.
Quality of the evidence
See Summary of findings for the main comparison
Overall we found the quality of evidence for most outcomes to be
of moderate to low quality, primarily due to risk of bias (particu-
larly non-blinding of the outcome assessor), and imprecision. Im-
precision was due in some cases, such as ’pain’, to few participants
but in other cases, such as mortality, to few events.
Limitations in study design and implementation
We assessed risk of bias according to six components: sequence
generation, allocation concealment, blinding, selective outcome
reporting, incomplete follow-up, and other potential biases. All of
the studies (except Nishanth 2009), avoided selection bias and en-
sured allocation concealment. We rated the evidence for method-
ological quality of most of the outcomes as moderate. It was not
possible to blind the intervention in any of the trials because it
was necessary to identify the catheter as either ’routine change’ or
’clinically indicated’, to prevent inadvertent routine replacement
of catheters in the intervention group. It is unclear if this had any
bearing on outcomes but we decided to downgrade one level for
all outcomes except CRBSI, where a blinded microbiologist di-
agnosed the condition. However, as one trial author noted, it is
routine practice to record reasons for removal of an IV catheter
in the medical record, and it is unlikely that such entries would
be falsified based on group allocation (Webster 2008). In Barker
2004 and Nishanth 2009, the investigator was directly involved
21Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in diagnosing phlebitis; in all of the other studies either medical
staff, ward nurses, IV therapy staff, or research nurses evaluated
the outcomes.
Indirectness of evidence
All of the trials compared routine changes with clinically indicated
changes. However, seven trials used a three to four-day change
schedule and two trials changed catheters every two days. Con-
sequently, three to four-day results may provide indirect evidence
for two-day changes, conversely two-day changes provide indirect
evidence for a three to four-day change schedule. Additionally,
only Nishanth 2009 included participants who were from a low-
income country and who were, “usually asthenic, many underhy-
drated/dehydrated on admission” (personal correspondence), so
the evidence may be regarded as indirect for these types of patients.
Unexplained heterogeneity or inconsistency of results
When we combined results of studies that investigated the effect
of different catheter replacement schedules on phlebitis, the het-
erogeneity was high. This was probably due to the different sched-
ules for the routine catheter changes or population differences, or
both. Small sample sizes may also have contributed to the extreme
results, which caused the heterogeneity. We tested these assump-
tions by performing a sensitivity analysis, removing two of the
nine studies. Results of all trials are presented in the review text
and of seven trials in the ’Summary of findings’ table (Summary
of findings for the main comparison).
Imprecision of results
Confidence intervals were wide in the pooled outcomes of CRBSI,
all-cause blood stream infection, local infection, mortality and
pain, indicating a high level of uncertainty around the effect size.
Further research is therefore very likely to have an important im-
pact on the confidence in the estimate of effect for these outcomes.
Publication bias
We feel confident that our comprehensive electronic searches,
handsearching, and searches of large clinical trials databases, iden-
tified all existing, published, randomised controlled trials address-
ing the review question. We also have an established international
network of researchers in the field of vascular access, who alert us
to new trials. We would have developed a funnel plot to detect
reporting bias, if we had included more than 10 studies in the
review.
Potential biases in the review process
Although the review authors were investigators in one or more
of the included trials, we followed clearly described procedures
to prevent potential biases in the review process. We conducted a
careful literature search and the methods we used were transparent
and reproducible. None of the review authors has any conflict of
interests.
Agreements and disagreements with other
studies or reviews
Our results concur with several, prospective observational stud-
ies, which found no additional risk in extending intravenous de-
vice (IVD) dwell times (Abolfotouh 2014; Catney 2001; White
2001). In addition, two implementation studies, which changed
their policies to replacing PIVCs only if clinical indications were
present, showed no increase in rates of PIVC-related infection
(Bolton 2015; De Vries 2016). In addition, Bolton 2015 reported
a significant cost saving with a 25% stock reduction. Similarly, in
the De Vries 2016 study, peripheral line start kits were reduced
by 48% in the year following the policy change. Two recently
published reviews, assessing the effect of changing PIVCs only
where a clinical indication exists also concurred with our results
(Morrison 2015; Patel 2017). Importantly, international and other
guidelines have been changed to reflect the results of this review
(Gorski 2016; Ho 2011; Loveday 2014). One of our outcomes
was catheter-related blood stream infection (CRBSI). We included
seven RCTs (over 7000 participants), and found no evidence that
dwell time had any effect on this outcome. In contrast, in another
systematic review, Mermel 2017 suggested that longer dwell times
resulted in higher CRBSI rates. The reason for the discrepancy
between the two reviews is the inclusion criteria. We included only
RCTs whereas Mermel 2017 included incidence studies, quality
improvement studies, quasi-experimental designs and a number
of RCTs where difference in dwell time was not the focus of the
study. When participants are not randomised, or not randomised
for the purpose of assessing the effect of dwell time on catheter-
related outcomes, a potential for bias exists. For example, the sick-
est participants, those most likely to develop a CRBSI, are also
those who would be expected to have their catheters in place for
longer periods. Randomisation ensures risk factors that may affect
the outcome, are equally distributed between groups.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review update found moderate to low-certainty evidence of
no clear difference in rates of catheter-related bloodstream infec-
tion (CRBSI), thrombophlebitis, all-cause bloodstream infection,
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mortality or pain between clinically indicated or routine replace-
ment of peripheral intravenous catheters. We are uncertain if local
infection is reduced or increased when catheters are changed when
clinically indicated. There is moderate-certainty evidence that in-
filtration and catheter blockage is probably lower when PIVC are
changed routinely; and moderate-certainty evidence that clini-
cally indicated removal probably reduces device-related costs. The
consistency in these results, which include two very large multi-
site studies, indicate that healthcare organisations should consider
changing to a policy whereby catheters are changed only if there
is a clinical indication to do so, for example, if there were signs of
infection, blockage or infiltration. This would provide significant
cost savings and would also be welcomed by patients, who would
be spared the unnecessary pain of routine re-sites in the absence of
clinical indications. Time spent by busy clinical staff on this inter-
vention would also be reduced. To minimise peripheral catheter-
related complications, the insertion site should be inspected at
each shift change and the catheter removed if signs of inflamma-
tion, infiltration, or blockage are present, or as soon as therapy is
completed.
Implications for research
Based on results from the meta-analyses in this review, a sample
size of greater than 25,000 participants would be required to show
clear differences between groups for the most important outcomes
in this review, that is CRBSI and phlebitis. Consequently, it is
unlikely that such a trial is warranted, given the low event rate for
CRBSI and the very high number needed to treat (almost 1700)
for one patient to avoid phlebitis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barker 2004
Methods Study design: single-centre RCT
Method of randomisation: computer-generated
Concealment of allocation: sealed envelopes
Participants Country: England, UK
Number: 47 patients in general medical or surgical wards. Clinically indicated: 43
catheters were inserted in 26 participants. Routine replacement: 41 catheters were in-
serted in 21 participants
Age: clinically indicated 60.5 years (15.5); routine replacement 62.7 years (18.2)
Sex (M/F): clinically indicated 15/11; routine replacement 14/7
Inclusion criteria: hospital inpatients receiving crystalloids and drugs
Exclusion criteria: not stated
Interventions Clinically indicated: catheters were removed if the site became painful, the catheter
dislodged or there were signs of PVT
Routine replacement: catheters were replaced every 48 h
Outcomes Primary: incidence of PVT defined as “the development of two or more of the following:
pain, erythema, swelling, excessive warmth or a palpable venous cord”
Notes PVT was defined as “the development of two or more of the following: pain, erythema,
swelling, excessive warmth or a palpable venous cord”. However, in the discussion, the
trial author stated that “even a small area of erythema was recorded as phlebitis” (i.e.
only 1 sign)
It is unclear what proportion of participants were on continuous infusion
Catheters were inserted “at the instruction of the principal investigator”
“All patients were reviewed daily by the principal investigator, and examined for signs of
PVT at the current and all previous infusion sites”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: computer-generated (personal
communication with trial author)
Allocation concealment (selection bias) Low risk Comment: sealed envelopes (personal
communication with trial author)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence: “Forty-seven patients were in-
cluded in this randomised, controlled, un-
blinded study”
Comment: classified as high risk because
the investigator was involved in all stages of
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Barker 2004 (Continued)
the study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence: “Forty-seven patients were in-
cluded in this randomised, controlled, un-
blinded study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: in this small sample, there were
five fewer participants in the routine re-
placement group. No explanation was pro-
vided for the unequal sample size. No drop-
outs or loss to follow-up were reported
Selective reporting (reporting bias) Low risk Comment: Phlebitis was the only outcome
planned.
Other bias High risk Comment: the chief investigator allocated
participants and was responsible for out-
come evaluation
No sample size calculation
Nishanth 2009
Methods Study design: single-centre RCT
Method of randomisation: not stated.
Concealment of allocation: sequentially numbered, sealed envelopes
Participants Country: India
Number: 42 patients in surgical wards. Clinically indicated: 21. Routine replacement:
21
Age: clinically indicated 40.2 years (15.0); routine replacement 42.9 years (15.0)
Sex (M/F): clinically indicated 17/4; routine replacement 16/5
Inclusion criteria: hospital inpatients admitted for major abdominal surgery
Exclusion criteria: receiving total parenteral nutrition, duration of therapy expected to
be < 3 days, if a cannula was already in situ, terminally ill patients
Interventions Clinically indicated: catheters were removed if the site became painful, the catheter
dislodged or there were signs of PVT
Routine replacement: catheters were replaced every 48 h
Outcomes Primary: incidence of PVT defined as “the development of two or more of the following:
pain, erythema, swelling, excessive warmth or a palpable venous cord”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Evidence: “The patients were allocated to
either study or the control group using
block randomisation method. The patients
were divided into 6 blocks with block sizes
of 8 or 10 or 12 arranged randomly”
Comment: how the sequence was gener-
ated was not stated. With group sizes of 21
per group, that block sizes make no sense
Allocation concealment (selection bias) High risk Evidence: “Group name was placed (on) an
opaque serially numbered sealed envelope
(SNOSE).”
Comment: presumably the trial authors
meant ’in’ an opaque serially numbered
sealed envelope - based on subsequent in-
formation. The investigator was responsi-
ble for allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence: “..unblinded study”
Comment: neither participants nor clinical
personnel were blinded but review authors
do not believe this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence: “...unblinded study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: data for all participants were
available
Selective reporting (reporting bias) Low risk Comment: stated outcomes were reported
but original protocol not sighted
Other bias High risk Extreme results: in this small trial, 100%
of participants in the clinically indicated
group developed phlebitis compared with
9% in the 2-day change group, which sug-
gests that chance or other unknown bias af-
fected results
Rickard 2010
Methods Study design: single-centre RCT
Method of randomisation: computer-generated
Concealment of allocation: telephone service
Participants Country: Australia
Number: 362 patients requiring IV therapy in general medical or surgical wards. Clin-
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Rickard 2010 (Continued)
ically indicated: 280 catheters were inserted in 185 participants. Routine replacement:
323 catheters were inserted in 177 participants
Age: clinically indicated 62.7 years (15.5); routine replacement 65.1 years (17.3)
Sex (M/F): clinically indicated 82/103; routine replacement 81/91
Inclusion criteria: > 18 years, expected to have an IVD, requiring IV therapy for ≥ 4
days
Exclusion criteria: patients who were immunosuppressed, had an existing BSI or those
in whom an IVD had been in place for > 48 h
Interventions Clinically indicated: catheters were removed if there were signs of phlebitis, local infec-
tion, bacteraemia, infiltration or blockage
Routine replacement: catheters were replaced every 72-96 h
Outcomes Primary: phlebitis per person and per 1000 IVD days (defined as ≥ 2 of the following:
pain, erythema, purulence, infiltration, palpable venous cord); IVD-related bacteraemia
Secondary: hours of catheterisation; number of IV devices; device-related BSI; infiltra-
tion; local infection
Notes Approximately 75% of participants were receiving a continuous infusion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “Patients were randomly as-
signed (computer generated)”
Allocation concealment (selection bias) Low risk Evidence: “Assignment was concealed un-
til randomisation by use of a telephone ser-
vice”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence: “Open (non-blinded) parallel
group RCT”
Comment: neither participants nor clinical
personnel were blinded but review authors
do not believe this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: although laboratory staff were
blinded for microbiological outcomes,
there were no BSIs; consequently, all other
outcome assessment was at high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: results from all enrolled partic-
ipants were reported
Selective reporting (reporting bias) Low risk Comment: the protocol was available. All
nominated outcomes were reported
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Other bias Unclear risk Comment: significantly more participants
in the routine-change group received IV an-
tibiotics (73.1% versus 62.9%)
Rickard 2012
Methods Study design: multicentre RCT
Method of randomisation: computer-generated, stratified by site
Concealment of allocation: allocation concealed until eligibility criteria was entered
into a hand-held computer
Participants Country: Australia
Number: 3283 patients requiring IV therapy in general medical or surgical wards. Clin-
ically indicated: 1593 participants. Routine replacement: 1690 participants
Age: clinically indicated 55.1 years (18.6); routine replacement 55.0 years (18.4)
Sex (M/F): clinically indicated 1022/571; routine replacement 1034/656
Inclusion criteria: patients, or their representative able to provide written consent; > 18
years, expected to have an IVD in situ, requiring IV therapy for ≥ 4 days
Exclusion criteria: patients who were immunosuppressed, had an existing BSI or those
in whom an IVD had been in place for > 48 h or it was planned for the catheter to be
removed < 24 h
Interventions Clinically indicated: catheters were removed if there were signs of phlebitis, local infec-
tion, bacteraemia, infiltration or blockage
Routine replacement: catheters were replaced every 72-96 h
Outcomes Primary: phlebitis during catheterisation or within 48 h of removal (defined as ≥ 2 of
the following: pain, erythema, swelling, purulent discharge, palpable venous cord)
Secondary: CRBSI, all-cause BSI, local venous infection, colonisation of the catheter




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “Random allocations were com-
puter-generated”
Allocation concealment (selection bias) Low risk Evidence: “Random allocations were com-
puter-generated on a hand-held device, at
the point of each patient’s entry, and thus
were concealed to patients, clinical staff and
research staff until this time”
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Rickard 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence: “Patients and clinical staff could
not be blinded ........Research nurses were
similarly not masked”
Comment: neither participants nor clinical
personnel were blinded but review authors
do not believe this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence: “... laboratory staff were masked
for rating of all microbiological end-points,
and a masked, independent medical rater
diagnosed catheter-related infections and
all bloodstream infections”
Comment: diagnosis of all other outcomes
was unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis reported
Selective reporting (reporting bias) Low risk The protocol was available and all pre-de-
fined outcomes were reported
Other bias Low risk No other known risks of bias
Van Donk 2009
Methods Study design: RCT
Method of randomisation: computer-generated
Concealment of allocation: sealed envelopes
Participants Country: Australia
Number: 200. Clinically indicated: 105 participants. Routine replacement: 95 partici-
pants
Age: clinically indicated 62.8 years (18.2); routine replacement 54.5 years (19.0)
Sex (M/F): not stated
Inclusion criteria: adult patients who could be treated at home for an acute illness and
had a 20-, 22-, or 24-gauge catheter inserted in an upper extremity
Exclusion criteria: not stated
Interventions Clinically indicated: catheters were removed if there were signs of phlebitis, local infec-
tion, bacteraemia, infiltration or blockage
Routine replacement: catheters were replaced every 72-96 h
Outcomes Primary: phlebitis per participant and per 1000 device days (phlebitis was defined as a
total score of ≥ 2 points from the following factors: pain (on a 10-point scale, 1 = 1 point,
and ≥ 2 = 2 points; redness (< 1 cm = 1 point, and ≥ 1 cm = 2 points); swelling (as for
redness); and discharge (haemoserous ooze under dressing = 1 point, and haemoserous
ooze requiring dressing change or purulence = 2 points)
Also reported on: suspected IVD-related bacteraemia and occlusion/blockage
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: computer-generated allocation
(personal communication with trial au-
thor)
Allocation concealment (selection bias) Low risk Evidence:: “Randomization was concealed
until treatment via sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: neither participants nor clinical
personnel were blinded but review authors
do not believe this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessment unable to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: participant flow chart pro-
vided. Results from all enrolled participants
were reported
Selective reporting (reporting bias) Low risk Comment: all planned outcomes were re-
ported
Other bias Low risk No other known risks of bias
Vendramim 2018
Methods Study design: multicentre, non-inferiority, RCT
Method of randomisation: computer-generated
Concealment of allocation: sequentially numbered, sealed envelopes
Participants Country: Brazil
Number: 1319. Clinically indicated: 672 participants. Routine replacement: 647 par-
ticipants
Age: clinically indicated 59.7 (20.9); routine replacement 59.9 years (20.1)
Sex (M/F): clinically indicated 339/333; routine replacement 318/329
Inclusion criteria:
• “aged at least 18 years, expected use of PIVC for at least 96 hours, patients with
PIVC inserted in data collection units (wards), intensive care units or surgical centres
and accepted of the proposals expressed in the Informed Consent Form by the patient
or by someone responsible for the patient. Patients aged eighteen and older, from two
Säo Paulo City hospital” (personal communication)
Exclusion criteria:
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• “blood stream infection and or sepsis, neutrophil less than or equal to 1000/mm3
and simultaneous use of more than one PIVC” (personal communication)
Interventions Clinically indicated: catheters were removed according to clinical signs
Routine replacement: catheters were replaced systematically every 96 h
Outcomes Primary: phlebitis
Secondary: pain; infiltration; occlusion; accidental removal; extravasation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “A computerized randomization
program (random.org), a list prepared in
blocks of six patients and stratified by ward
and per hospital. Thus, each ward had its
own randomization list, totaling 10 lists of
randomization, six in Hospital A and four
in Hospital B”. (Personal communication)
Allocation concealment (selection bias) Low risk Evidence: “At the moment of the recruit-
ment, that is, after the acceptance of the
patient, the assistants have sent a message
from a App (whatsApp) and I indicated the
group”
Comment: the person providing the allo-
cation was unaware of the status of the po-
tential participant and the person recruit-
ing the participant was unaware of the al-
location sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: neither participants nor clinical
personnel were blinded but review authors
do not believe this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded study
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses in either group. ITT analysis
available
Selective reporting (reporting bias) Low risk Expected outcomes reported. Consistent
with ClinicalTrials.gov entry
Other bias Low risk None detected
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Webster 2007
Methods Study design: single-centre RCT
Method of randomisation: computer-generated
Concealment of allocation: allocation concealed until telephone contact made with an
independent person
Participants Country: Australia
Number: 206. Clinically indicated: 103 participants. Routine replacement: 103 partic-
ipants
Age: clinically indicated 60.2 years (16.2); routine replacement 63.1 years (17.3)
Sex (M/F): clinically indicated 53/50; routine replacement 54/49
Inclusion criteria: ≥ 18 years of age, expected to have an IVD in situ, requiring IV
therapy for ≥ 4 days, catheter inserted by a member of the IV team
Exclusion criteria: immunosuppressed patients and those with an existing BSI
Interventions Clinically indicated: catheters removed if there were signs of phlebitis, local infection,
bacteraemia, infiltration or blockage
Routine replacement: catheters replaced every 3 days
Outcomes Primary: composite measure of any reason for an unplanned catheter removal
Secondary: cost:
• for intermittent infusion: 20 min nursing/medical time, a cannula, a 3-way tap, a
basic dressing pack, gloves, a syringe, transparent adhesive dressing, skin disinfection
and local anaesthetic per insertion.
• for participants receiving a continuous infusion: all the above costs plus the
additional cost of replacing all associated lines, solutions and additives that are




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “Randomization was by com-
puter generated random number list, strat-
ified by oncology status”
Allocation concealment (selection bias) Low risk Evidence: “Allocation was made by phon-
ing a person who was independent of the
recruitment process”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence: “Clinical staff were subse-
quently aware of the treatment group”
Comment: neither participants nor clinical
personnel were blinded but reviewers do
not believe this would introduce bias
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Webster 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence: “Research staff had no involve-
ment in nominating the reason for catheter
removal or in diagnosing phlebitis”
Comment: diagnosis of all outcomes were
unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all recruited participants were
accounted for in the results
Selective reporting (reporting bias) Low risk Comment: protocol was available. All
planned outcomes were reported
Other bias Low risk No other known risks of bias
Webster 2008
Methods Study design: single-centre RCT
Method of randomisation: computer-generated
Concealment of allocation: telephone randomisation
Participants Country: Australia
Number: 755. Clinically indicated: 379 participants. Routine replacement: 376 partic-
ipants
Age: clinically indicated 60.1 years (17.1); routine replacement 58.8 years (18.8)
Sex (M/F): clinically indicated 248/131; routine replacement 233/143
Inclusion criteria: ≥ 18 years of age, expected to have a IVD in situ, requiring IV
therapy for ≥ 4 days
Exclusion criteria: immunosuppressed patients and those with an existing BSI
Interventions Clinically indicated: catheter removed if there were signs of phlebitis, local infection,
bacteraemia, infiltration or blockage
Routine replacement: catheter replaced every 3 days
Outcomes Primary: a composite measure of phlebitis (defined as ≥ 2 of the following: pain,
erythema, purulence, infiltration, palpable venous cord) and infiltration
Secondary:
• infusion-related costs.
◦ for intermittent infusion: 20-min nursing/medical time, a cannula, a 3-way
tap, a basic dressing pack, gloves, a syringe, transparent adhesive dressing, skin
disinfection and local anaesthetic per insertion
◦ for continuous infusion: all the above costs plus the additional cost of
replacing all associated lines, solutions and additives that are discarded when an IV
catheter is changed (based on an IV administration set, 1 L sodium chloride 0.09%)
• Individual reasons for catheter failure (occlusion/blockage, local infection)
Also reported: bacteraemia rate
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “Block randomisation was by a
computer generated random number list”
Allocation concealment (selection bias) Low risk Evidence: “.... telephoned a contact who
was independent of the recruitment process
for allocation consignment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence: “Allo-
cation concealment avoided selection bias
but clinical staff were subsequently aware
of the treatment group”
Comment: neither participants nor clinical
personnel were blinded but review authors
do not believe this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence: “Staff in the microbiological lab-
oratory were blind to group assignment of
catheters submitted for testing”
Comment: all other outcomes were un-
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All recruited participants were accounted
for in the results
Selective reporting (reporting bias) Low risk Protocol was available. All planned out-
comes were reported
Other bias Low risk No other known risks of bias
Xu 2017
Methods Study design: cluster-RCT of 20 wards in a tertiary referral hospital in China
Method of randomisation: coin toss
Concealment of allocation: coin toss
Participants Country: China
Number: clinically indicated: 553 patients. Routine replacement: 645 patients
Age: clinically indicated 58.7 years (39.7); routine replacement 56.2 years (27.1)
Sex (M/F): clinically indicated 325/208; routine replacement 335/310
Inclusion criteria: adult patients > 18 years of age who received catheter infusion;
patients who were expected to use the indwelling catheter for ≥ 3 days; patients who used
PIVCs for the first time during hospitalisation; and patients who agreed to participate
in this study
Exclusion criteria: patients with BSI or under immunosuppressive therapy; patients
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receiving parenteral nutrition infusion through PIVC; patients with indwelling catheters
for > 72 h at study entry; and severe infection or hepatocellular failure and renal failure
Interventions Intervention: PIVCs were removed/replaced if there was a clinical indication to do so
Control: PIVCs were replaced every 3 days in the control group (the routine-replacement
group) following hospital policy. The duration of ’3 days’ refers to the approximate 72
h (range: 48-96 h) from the time of insertion to removal of a catheter. They were also
removed/replaced if there was a clinical indication to do so
Outcomes Primary: incidence of phlebitis: defined as when ≥ 2 of the following signs occurred at
the catheter access site: redness, swelling, fever, pain, or palpable cord-like veins
Secondary: fluid infiltration (when the infused non-blister drug leaked into the sur-
rounding tissue from the normal vascular access, causing tissue swelling around the
catheter access site); catheter occlusion (when the drug fluid could not flow into the body
or the fluid could not be withdrawn); accidental catheter removal; CRBSI (diagnosed
when signs of infection (e.g. fever, chills, and hypotension), positive results, and the same
type of bacteria were found in bacterial cultures of both peripheral venous blood and the
PIVC tip, and no other apparent source of BSI other than the IV catheter was observed
(including BSI within 48 hours of catheter indwelling); local venous infection, i.e. pu-




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Evidence: “These 20 internal medicine and
surgery ward patients were randomly as-
signed by a research assistant via a coin toss
into 2 groups”
Allocation concealment (selection bias) Low risk Evidence: “These 20 internal medicine and
surgery ward patients were randomly as-
signed by a research assistant via a coin toss
into 2 groups”
Comment: allocation remains concealed
until the coin is tossed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence for participants: “All of the par-
ticipating patients were not blinded in the
groups”
Evidence for personnel: “Because of the
nature of the intervention in this study, the
chief nurse in charge of the research wards
and the clinical nurses were not blinded to
the random grouping”
Comment: neither participants nor clinical
38Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Xu 2017 (Continued)
personnel were blinded but review authors
do not believe this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence: “The peripheral blood samples
and the catheter tips of patients with sus-
pected CRBSI were sent for laboratory ex-
amination, and the laboratory examiners
were blinded”
Comment: blinding not possible for other
outcomes and there was no laboratory con-
firmed diagnosis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: complete data reporting for all
outcomes: after 235 people, who were po-
tentially eligible by belonging to a ward that
was randomised, were excluded. 1198 par-
ticipants were included for the final analy-
sis (flow chart included)
Selective reporting (reporting bias) Low risk Comment: expected outcomes reported
Other bias Unclear risk Comment: this was a cluster trial but anal-
ysed by individual not cluster
BSI: blood stream infection; CRBSI: catheter-related blood stream infection; ITT: intention-to-treat; IV: intravenous; IVD: peripheral
intravenous device; PIVC: peripheral intravenous catheter; PVT: peripheral vein infusion thrombophlebitis; RCT: randomised
controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnold 1977 Not a RCT
Cobb 1992 Involved central, not peripheral lines
Eyer 1990 Involved pulmonary artery or arterial catheters, not peripheral catheters
Haddad 2006 End point was lymphangitis
Kerin 1991 Participants were receiving parenteral nutrition
May 1996 Participants were receiving parenteral nutrition
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Nakae 2010 Involved central, not peripheral lines
Panadero 2002 Compared the use of a single intraoperative and postoperative catheters with 2 catheters, 1 used intraoperatively
and a separate catheter for postoperative use
Rijnders 2004 Involved central, not peripheral lines
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Chin 2018
Methods RCT 1:1
Participants 113 neonates born at ≥ 32 weeks’ gestation
Interventions PIVC replaced every 72-96 h or replaced when clinically indicated
Outcomes Primary: extravasation
Secondary: phlebitis; leakage; accidental dislodgement
Notes No response to request for additional data as yet
PIVC: peripheral intravenous catheter; RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Clinically-indicated versus routine change




participants Statistical method Effect size
1 Catheter-related blood stream
infection
7 7323 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.08, 4.68]
2 Phlebitis 7 7323 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.93, 1.25]
2.1 Continuous infusion 6 7123 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.90, 1.23]
2.2 Intermittent infusion 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.85, 1.96]
3 Phlebitis per device days 6 32709 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.76, 1.08]
4 All-cause blood stream infection 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Cost 3 4244 Mean Difference (IV, Fixed, 95% CI) -6.96 [-9.05, -4.86]
6 Infiltration 6 7123 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.06, 1.26]
7 Catheter blockage 7 7323 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [1.02, 1.27]
8 Local infection 4 4606 Risk Ratio (M-H, Fixed, 95% CI) 4.96 [0.24, 102.98]
9 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Pain during infusion 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Clinically-indicated versus routine change, Outcome 1 Catheter-related blood
stream infection.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 1 Catheter-related blood stream infection
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 0/185 0/177 Not estimable
Rickard 2012 0/1593 1/1690 59.2 % 0.35 [ 0.01, 8.67 ]
Van Donk 2009 0/105 0/95 Not estimable
Vendramim 2018 0/672 0/647 Not estimable
Webster 2007 0/103 0/103 Not estimable
Webster 2008 1/379 1/376 40.8 % 0.99 [ 0.06, 15.80 ]
Xu 2017 0/553 0/645 Not estimable
Total (95% CI) 3590 3733 100.0 % 0.61 [ 0.08, 4.68 ]
0.01 0.1 1 10 100
Favours cl-indicated Favours 3-day
(Continued . . . )
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Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1 (Clinically indicated), 2 (Routine replacement)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours cl-indicated Favours 3-day
Analysis 1.2. Comparison 1 Clinically-indicated versus routine change, Outcome 2 Phlebitis.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 2 Phlebitis
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Continuous infusion
Rickard 2010 18/185 12/177 4.1 % 1.44 [ 0.71, 2.89 ]
Rickard 2012 114/1593 114/1690 36.8 % 1.06 [ 0.83, 1.36 ]
Vendramim 2018 55/672 64/647 21.7 % 0.83 [ 0.59, 1.17 ]
Webster 2007 1/103 2/103 0.7 % 0.50 [ 0.05, 5.43 ]
Webster 2008 16/379 12/376 4.0 % 1.32 [ 0.63, 2.76 ]
Xu 2017 76/553 77/645 23.7 % 1.15 [ 0.86, 1.55 ]
Subtotal (95% CI) 3485 3638 90.9 % 1.05 [ 0.90, 1.23 ]
Total events: 280 (Clinically indicated), 281 (Routine replacement)
Heterogeneity: Chi2 = 3.74, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Intermittent infusion
Van Donk 2009 37/105 26/95 9.1 % 1.29 [ 0.85, 1.96 ]
Subtotal (95% CI) 105 95 9.1 % 1.29 [ 0.85, 1.96 ]
Total events: 37 (Clinically indicated), 26 (Routine replacement)
Heterogeneity: not applicable
0.05 0.2 1 5 20
Favours cl-indicated Favours 3-day
(Continued . . . )
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Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.19 (P = 0.24)
Total (95% CI) 3590 3733 100.0 % 1.07 [ 0.93, 1.25 ]
Total events: 317 (Clinically indicated), 307 (Routine replacement)
Heterogeneity: Chi2 = 4.52, df = 6 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
0.05 0.2 1 5 20
Favours cl-indicated Favours 3-day
Analysis 1.3. Comparison 1 Clinically-indicated versus routine change, Outcome 3 Phlebitis per device days.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 3 Phlebitis per device days
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 18/1120 12/970 5.1 % 1.30 [ 0.63, 2.68 ]
Rickard 2012 114/8693 114/8719 44.8 % 1.00 [ 0.77, 1.30 ]
Van Donk 2009 37/698 26/508 11.9 % 1.04 [ 0.64, 1.69 ]
Vendramim 2018 62/3825 70/2693 32.4 % 0.62 [ 0.44, 0.87 ]
Webster 2007 1/522 2/548 0.8 % 0.52 [ 0.05, 5.77 ]
Webster 2008 16/2393 12/2020 5.1 % 1.13 [ 0.53, 2.37 ]
Total (95% CI) 17251 15458 100.0 % 0.90 [ 0.76, 1.08 ]
Total events: 248 (Clinically indicated), 236 (Routine replacement)
Heterogeneity: Chi2 = 7.04, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 1.4. Comparison 1 Clinically-indicated versus routine change, Outcome 4 All-cause blood stream
infection.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 4 All-cause blood stream infection
Study or subgroup Clinically indicated Routine replacement Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2012 4/1593 9/1690 0.47 [ 0.15, 1.53 ]
0.01 0.1 1 10 100
Favours cl-indicated Favours 3-day
Analysis 1.5. Comparison 1 Clinically-indicated versus routine change, Outcome 5 Cost.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 5 Cost





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rickard 2012 1593 61.66 (39.46) 1690 69.24 (43.45) 54.5 % -7.58 [ -10.42, -4.74 ]
Webster 2007 103 29.7 (16.4) 103 37.6 (20.2) 17.4 % -7.90 [ -12.92, -2.88 ]
Webster 2008 379 41.05 (26.6) 376 46.22 (28.7) 28.1 % -5.17 [ -9.12, -1.22 ]
Total (95% CI) 2075 2169 100.0 % -6.96 [ -9.05, -4.86 ]
Heterogeneity: Chi2 = 1.11, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 6.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Clinically-indicated versus routine change, Outcome 6 Infiltration.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 6 Infiltration
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 61/185 53/177 7.4 % 1.10 [ 0.81, 1.49 ]
Rickard 2012 279/1593 235/1690 31.2 % 1.26 [ 1.07, 1.48 ]
Vendramim 2018 172/672 134/647 18.7 % 1.24 [ 1.01, 1.51 ]
Webster 2007 43/103 44/103 6.0 % 0.98 [ 0.71, 1.35 ]
Webster 2008 135/379 120/376 16.5 % 1.12 [ 0.91, 1.36 ]
Xu 2017 144/553 161/645 20.3 % 1.04 [ 0.86, 1.27 ]
Total (95% CI) 3485 3638 100.0 % 1.16 [ 1.06, 1.26 ]
Total events: 834 (Clinically indicated), 747 (Routine replacement)
Heterogeneity: Chi2 = 3.92, df = 5 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00077)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Clinically-indicated versus routine change, Outcome 7 Catheter blockage.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 7 Catheter blockage
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 4/185 5/177 1.0 % 0.77 [ 0.21, 2.80 ]
Rickard 2012 344/1593 344/1690 66.2 % 1.06 [ 0.93, 1.21 ]
Van Donk 2009 13/105 4/95 0.8 % 2.94 [ 0.99, 8.71 ]
Vendramim 2018 80/672 61/647 12.3 % 1.26 [ 0.92, 1.73 ]
Webster 2007 7/103 4/103 0.8 % 1.75 [ 0.53, 5.80 ]
Webster 2008 30/379 20/376 4.0 % 1.49 [ 0.86, 2.57 ]
Xu 2017 82/553 81/645 14.8 % 1.18 [ 0.89, 1.57 ]
Total (95% CI) 3590 3733 100.0 % 1.14 [ 1.02, 1.27 ]
Total events: 560 (Clinically indicated), 519 (Routine replacement)
Heterogeneity: Chi2 = 6.27, df = 6 (P = 0.39); I2 =4%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 1.8. Comparison 1 Clinically-indicated versus routine change, Outcome 8 Local infection.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 8 Local infection
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 0/185 0/177 Not estimable
Rickard 2012 0/1593 0/1690 Not estimable
Webster 2007 0/103 0/103 Not estimable
Webster 2008 2/379 0/376 100.0 % 4.96 [ 0.24, 102.98 ]
Total (95% CI) 2260 2346 100.0 % 4.96 [ 0.24, 102.98 ]
Total events: 2 (Clinically indicated), 0 (Routine replacement)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.9. Comparison 1 Clinically-indicated versus routine change, Outcome 9 Mortality.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 9 Mortality
Study or subgroup Clinically indicated Routine replacement Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2012 4/1593 4/1690 1.06 [ 0.27, 4.23 ]
0.01 0.1 1 10 100
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Analysis 1.10. Comparison 1 Clinically-indicated versus routine change, Outcome 10 Pain during infusion.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 10 Pain during infusion





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vendramim 2018 104 4.6 (3) 94 5.2 (3) -0.60 [ -1.44, 0.24 ]
-10 -5 0 5 10
Favours cl-indicated Favours 3-day
A P P E N D I C E S
Appendix 1. Search strategies
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Cochrane Central Register of Controlled
Trials (1 January 2015 to 18 April 2018)
#1 MESH DESCRIPTOR Infusions, In-
travenous EXPLODE ALL TREES 9657
#2 MESH DESCRIPTOR Catheters, In-
dwelling EXPLODE ALL TREES 933
#3 MESH DESCRIPTOR Catheteriza-




#6 (iv near2 (therapy or treatment or de-
vice)):TI,AB,KY 817
#7 (intravenous near2 (therapy or treat-
ment or device)):TI,AB,KY 2643
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #
6 OR #7 32660
#9 MESH DESCRIPTOR Device Re-
moval EXPLODE ALL TREES 340
#10 change:TI,AB,KY 100383
#11 routine:TI,AB,KY 22763
#12 (resit* or re-sit* ):TI,AB,KY 28
#13 replace* :TI,AB,KY 23906
#14 remov* 18920
#15 #9 OR #10 OR #11 OR #12 OR #13
OR #14 157711
#16 #8 AND #15 6531
#17 01/01/2015 TO 17/04/2018:CD
301940
#18 #16 AND #17 1946
1946
US National Institutes of Health Ongo-
ing Trials Register ClinicalTrials.gov (www.
clinicaltrials.gov; (1 January 2015 to 18
April 2018))
catheter* OR cannul* OR Intravenous In-
fusions | change OR routine OR replace*
OR remov*
66
World Health Organization International
Clinical Trials Registry Platform (1 January
2015 to 18 April 2018)
change OR routine OR replace* OR re-
mov* AND catheter* OR cannul* OR In-
travenous Infusions
103
Medline (Ovid MEDLINE® Epub Ahead
of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE® Daily and
Ovid MEDLINE® 1 January 2017 to 18
April 2018)
1 exp Infusions, Intravenous/ 52357
2 exp Catheters, Indwelling/ 17598
3 exp Catheterization, Peripheral/ 10253
4 catheter*.ti,ab. 183558
5 cannul*.ti,ab. 40302
6 (iv adj2 (therapy or treatment or device)
).ti,ab. 5132
7 (intravenous adj2 (therapy or treatment
or device)).ti,ab. 16429
8 1 or 2 or 3 or 4 or 5 or 6 or 7 293380
9 exp Device Removal/ 11178
725
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16 8 and 15 48953
17 randomized controlled trial.pt. 458816
18 controlled clinical trial.pt. 92332
19 randomized.ab. 409164
20 placebo.ab. 188261





26 exp animals/ not humans.sh. 4446961
27 25 not 26 3616731
28 16 and 27 12988
29 (2017* or 2018*).ed. 1226025
30 28 and 29 725
Embase 1974 to present via Ovid (1 Jan-
uary 2017 to 18 April 2018)
1 exp intravenous drug administration/
369547
2 exp indwelling catheter/ 13600
3 exp catheterization/ 165359
4 catheter*.ti,ab. 271161
5 cannul*.ti,ab. 54348
6 (iv adj2 (therapy or treatment or device)
).ti,ab. 9056
7 (intravenous adj2 (therapy or treatment
or device)).ti,ab. 22346
8 or/1-7 771672
9 exp device removal/ 23201
10 change.ti,ab. 1179753
11 routine.ti,ab. 367917




16 8 and 15 101630
17 randomized controlled trial/ 498849
18 controlled clinical trial/ 460351
19 random$.ti,ab. 1293791
20 randomization/ 77793
21 intermethod comparison/ 233320
22 placebo.ti,ab. 270839
23 (compare or compared or comparison).
ti. 465805
2866
50Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
24 ((evaluated or evaluate or evaluating or
assessed or assess) and (compare or com-
pared or comparing or comparison)).ab.
1727440
25 (open adj label).ti,ab. 63597
26 ((double or single or doubly or singly)
adj (blind or blinded or blindly)).ti,ab.
207274
27 double blind procedure/ 148944
28 parallel group$1.ti,ab. 21584
29 (crossover or cross over).ti,ab. 92096
30 ((assign$ or match or matched or allo-
cation) adj5 (alternate or group$1 or in-
tervention$1 or patient$1 or subject$1 or
participant$1)).ti,ab. 279492
31 (assigned or allocated).ti,ab. 328034
32 (controlled adj7 (study or design or trial)
).ti,ab. 291440
33 (volunteer or volunteers).ti,ab. 222779
34 trial.ti. 247887
35 or/17-34 3991617
36 16 and 35 23176
37 (2017* or 2018*).em. 3311287
38 36 and 37 2866
CINAHL EBSCO (Cumulative Index to
Nursing and Allied Health Literature 1 Jan-
uary 2017 to 18 April 2018)
S32 S30 AND S31 163
S31 EM 2018 OR EM 2017 316,890
S30 S16 AND S29 2,084
S29 S17 OR S18 OR S19 OR S20 OR S21
OR S22 OR S23 OR S24 OR S25 OR S26
OR S27 OR S28 337,787
S28 (MH “Random Assignment”) 37,759
S27 (MH “Single-Blind Studies”) or (MH
“Double-Blind Studies”) or (MH “Triple-
Blind Studies”) 32,600
S26 (MH “Crossover Design”) 11,106
S25 (MH “Factorial Design”) 914
S24 (MH “Placebos”) 8,344
S23 (MH “Clinical Trials”) 93,083
S22 TX “multi-centre study” OR “multi-
center study” OR “multicentre study” OR
“multicenter study” OR “multi-site study”
4,386
S21 TX crossover OR “cross-over” 14,384
S20 AB placebo* 27,965
S19 TX random* 216,193
S18 TX trial* 247,155
S17 TX “latin square” 141
S16 S8 AND S15 9,028
163
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(Continued)
S15 S9 OR S10 OR S11 OR S12 OR S13
OR S14 380,613
S14 TX remov* 35,451
S13 TX replace* 49,936
S12 TX (resit* or re-sit* ) 71
S11 TX routine 39,406
S10 TX change 279,795
S9 (MH “Device Removal+”) 2,141
S8 S1 OR S2 OR S3 OR S4 OR S5 OR
S6 OR S7 52,305
S7 TX (intravenous n2 (therapy or treat-
ment or device)) 7,224
S6 TX (iv n2 (therapy or treatment or de-
vice)) 1,512
S5 TX cannul* 3,489
S4 TX catheter* 38,647
S3 (MH “Catheterization, Peripheral+”) 2,
413
S2 (MH “Catheters+”) 8,493
S1 (MH “Infusions, Intravenous”) 5,632
AMED Ovid (Allied and Complementary
Medicine 1 January 2017 to 18 April 2018)
1 exp catheterization/ 179
2 catheter*.ti,ab. 413
3 cannul*.ti,ab. 138
4 (iv adj2 (therapy or treatment or device)
).ti,ab. 45
5 (intravenous adj2 (therapy or treatment
or device)).ti,ab. 89
6 1 or 2 or 3 or 4 or 5 732
7 “Device Removal”.ti,ab. 1
8 change.ti,ab. 10950
9 routine.ti,ab. 1844




14 6 and 13 106
15 exp CLINICAL TRIALS/ 3720
16 RANDOM ALLOCATION/ 314
17 DOUBLE BLIND METHOD/ 650
18 Clinical trial.pt. 1210
19 (clinic* adj trial*).tw. 5347
20 ((singl* or doubl* or trebl* or tripl*) adj




24 PROSPECTIVE STUDIES/ 1065
25 or/15-24 22298
1
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(Continued)
26 14 and 25 23
27 (“2017” or “2018”).yr. 699
28 26 and 27 1
W H A T ’ S N E W
Date Event Description
23 August 2018 New citation required but conclusions have not changed Searches re-run. Two new studies included. No new
studies excluded. One study awaiting classification. Text
updated. No change to conclusions
23 August 2018 New search has been performed Searches re-run. Two new studies included. No new
studies excluded. One study awaiting classification
H I S T O R Y
Protocol first published: Issue 2, 2009
Review first published: Issue 3, 2010
Date Event Description
25 March 2015 New citation required but conclusions have not changed Searches re-run. No additional studies included or ex-
cluded. Minor changes to the text to adhere to current
Cochrane standards
25 March 2015 New search has been performed Searches re-run. No additional studies included or ex-
cluded.
C O N T R I B U T I O N S O F A U T H O R S
JW: conceived the idea for the review, wrote the protocol, selected trials for inclusion, assessed methodological quality of trials and
extracted data, entered the data, developed the analysis plan for the update and drafted the review update, guarantor of the review.
SO: wrote the protocol, arbitrated on the selection of trials, assisted with data extraction, assessed methodological quality and assisted
in drafting the final review.
CR: critically reviewed the protocol before final submission, selected trials for inclusion, assessed methodological quality of trials,
extracted data, assisted with interpreting results and drafting of the final review.
NM: selected trials for inclusion, assessed methodological quality of trials, extracted data, and commented on the review update.
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bodies where the funds came from commercial suppliers. These sponsors (3M, Adhezion, Angiodynamics, BD-Bard, Baxter, Medtronic,
Centurion Medical, Entrotech Life Sciences, Cook, Smiths Medical) had no involvement in the study design, execution, analysis
or publication of these projects, had no control over the projects, and they were unrelated to the topic of this review. CR is an
academic researcher and her employer has received funding on her behalf for her to provide consultancies (expert advice, advisory
panel participation, and educational lectures about her research at professional symposia and other events) from ResQDevices, Smiths
Medical and BD-Bard.
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
2018 update
• We added funding source; ethics approval and consent; and prospective registration on a clinical trials register; to our data
extraction tool
• We also added the following outcome to the ’Summary of Findings’ table:
◦ all-cause blood stream infection
Previous updates
We changed the primary outcome to catheter-related bloodstream infection; and added all-cause bloodstream infection as a separate
primary outcome. This was to more closely differentiate between the two outcomes. The methodological quality assessment of the
included studies was updated to the Cochrane Collaboration tool for assessing risk of bias (Higgins 2017).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Catheter-Related Infections [∗prevention & control]; Catheterization, Peripheral [adverse effects; economics; ∗instrumentation];
Catheters, Indwelling [adverse effects]; Device Removal [∗standards]; Guideline Adherence; Incidence; Phlebitis [epidemiology; etiol-
ogy]; Randomized Controlled Trials as Topic; Thrombophlebitis [epidemiology; etiology]; Time Factors
MeSH check words
Humans
55Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
